ATE516366T1 - Regulierte aptamer-therapeutika - Google Patents

Regulierte aptamer-therapeutika

Info

Publication number
ATE516366T1
ATE516366T1 AT03771887T AT03771887T ATE516366T1 AT E516366 T1 ATE516366 T1 AT E516366T1 AT 03771887 T AT03771887 T AT 03771887T AT 03771887 T AT03771887 T AT 03771887T AT E516366 T1 ATE516366 T1 AT E516366T1
Authority
AT
Austria
Prior art keywords
aptamer therapeutics
regulated aptamer
therapeutic compositions
presented
methods
Prior art date
Application number
AT03771887T
Other languages
English (en)
Inventor
David Epstein
Charles Wilson
John Diener
Original Assignee
Archemix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix Corp filed Critical Archemix Corp
Application granted granted Critical
Publication of ATE516366T1 publication Critical patent/ATE516366T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
AT03771887T 2002-07-25 2003-07-25 Regulierte aptamer-therapeutika ATE516366T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39848602P 2002-07-25 2002-07-25
US39886302P 2002-07-25 2002-07-25
PCT/US2003/023402 WO2004011680A1 (en) 2002-07-25 2003-07-25 Regulated aptamer therapeutics

Publications (1)

Publication Number Publication Date
ATE516366T1 true ATE516366T1 (de) 2011-07-15

Family

ID=32475361

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03771887T ATE516366T1 (de) 2002-07-25 2003-07-25 Regulierte aptamer-therapeutika

Country Status (7)

Country Link
US (2) US20040110235A1 (de)
EP (1) EP1543158B1 (de)
JP (1) JP2005533862A (de)
AT (1) ATE516366T1 (de)
AU (1) AU2003261264B2 (de)
CA (1) CA2492463A1 (de)
WO (1) WO2004011680A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026932A2 (en) 2000-09-26 2002-04-04 Duke University Rna aptamers and methods for identifying the same
PT2070939E (pt) 2001-05-25 2014-06-09 Univ Duke Moduladores de agentes farmacológicos
FR2867784B1 (fr) * 2004-03-17 2006-06-09 Commissariat Energie Atomique Aptameres selectionnes a partir de cellules vivantes tumorales et leurs applications
CN1980947B (zh) 2004-04-22 2013-01-30 雷加多生物科学公司 改良的凝血因子调节物
AU2005245793A1 (en) * 2004-04-26 2005-12-01 Archemix Corporation Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics
US20090130650A1 (en) * 2006-02-17 2009-05-21 Weihong Tan Methods for the production of highly sensitive and specific cell surface probes
US20090117549A1 (en) * 2006-07-18 2009-05-07 Weihong Tan Aptamer-based methods for identifying cellular biomarkers
GB0719367D0 (en) 2007-10-03 2007-11-14 Procarta Biosystems Ltd Transcription factor decoys, compositions and methods
GB0906130D0 (en) * 2008-10-03 2009-05-20 Procrata Biosystems Ltd Transcription factor decoys
WO2010088286A1 (en) * 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
WO2010088276A2 (en) * 2009-01-28 2010-08-05 Smartcells, Inc. Polynucleotide aptamer-based cross -linked materials and uses thereof
WO2010129666A1 (en) * 2009-05-05 2010-11-11 Altermune Technologies, Llc Chemically programmable immunity
GB201002413D0 (en) 2010-02-12 2010-03-31 Procarta Biosystems Ltd Nucleic acid complexes
WO2014170899A1 (en) * 2013-04-18 2014-10-23 Bar-Ilan University Systems comprising non-immunogenic and nuclease resistant nucleic acid origami devices for molecular computation
WO2014170898A1 (en) * 2013-04-18 2014-10-23 Bar-Ilan University Non-immunogenic and nuclease resistant nucleic acid origami devices and compositions thereof
US10450573B2 (en) 2014-08-13 2019-10-22 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for regulation of gene expression with, and detection of, folinic acid and folates
US10724039B2 (en) * 2015-07-27 2020-07-28 Posco Aptamer against insulin receptor and pharmaceutical compostion containing the same
CN107083387A (zh) * 2016-10-17 2017-08-22 柳州立洁科技有限公司 一种高亲和力胰岛素核酸适体ins4及其制备方法
CN108613862B (zh) * 2018-05-10 2020-10-27 北京理工大学 一种基于毛细管电泳的双靶同步核酸适配体筛选方法
JP7696809B2 (ja) * 2020-10-30 2025-06-23 アークレイ株式会社 インフルエンザウイルスの核酸アプタマー及び検出
KR20230131326A (ko) * 2022-03-03 2023-09-13 주식회사 압타머사이언스 인슐린 수용체 특이적 압타머 및 이의 이용

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755295A (en) * 1969-10-24 1973-08-28 Syntex Corp 1-(2-amino-2-deoxy-{62 -d-ribofuranosyl) pyrimidines and derivatives thereof
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4959309A (en) * 1983-07-14 1990-09-25 Molecular Diagnostics, Inc. Fast photochemical method of labelling nucleic acids for detection purposes in hybridization assays
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3587814T2 (de) * 1985-03-30 1994-11-10 Marc Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US4935363A (en) * 1987-03-30 1990-06-19 Board Of Regents, The University Of Texas System Sterol regulatory elements
WO1989006694A1 (en) 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5118672A (en) * 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
US5070010A (en) * 1989-10-30 1991-12-03 Hoffman-La Roche Inc. Method for determining anti-viral transactivating activity
EP0503000A4 (en) * 1989-12-01 1993-04-14 The Board Of Trustees Of The Leland Stanford Junior University Promotion of high specificity molecular assembly
CA2078659A1 (en) 1990-03-21 1991-09-22 David J. Ecker Reagents and methods for modulating gene expression through rna mimicry
ATE154981T1 (de) * 1990-04-06 1997-07-15 Perkin Elmer Corp Automatisiertes labor für molekularbiologie
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5635615A (en) * 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
US5476766A (en) * 1990-06-11 1995-12-19 Nexstar Pharmaceuticals, Inc. Ligands of thrombin
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5654151A (en) * 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5496938A (en) * 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US6465189B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Systematic evolution of ligands by exponential enrichment: blended selex
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5637459A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5763173A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5789157A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6083696A (en) * 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
US5648214A (en) * 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
AU8547691A (en) 1990-09-21 1992-04-15 Fred Hutchinson Cancer Research Center Protein sequence-specific oligonucleotide sequences
AU649074B2 (en) 1990-10-12 1994-05-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
IE920562A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
IL101038A0 (en) 1991-02-21 1992-11-15 Gilead Sciences Inc Agent specific for trombin and its use
US5605662A (en) * 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US5720163A (en) * 1992-02-14 1998-02-24 Precision Combustion, Inc. Torch assembly
US5338671A (en) 1992-10-07 1994-08-16 Eastman Kodak Company DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
JPH08507203A (ja) * 1992-12-04 1996-08-06 イノーバー ラボラトリーズ，インコーポレイテッド 調節可能な核酸治療およびそれらの使用方法
ATE217347T1 (de) 1992-12-04 2002-05-15 Univ Yale Diagnose mittels signalverstärkung durch ein ribozym
US5817635A (en) * 1993-08-09 1998-10-06 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
US5998142A (en) 1993-09-08 1999-12-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US5663064A (en) 1995-01-13 1997-09-02 University Of Vermont Ribozymes with RNA protein binding site
US6013443A (en) * 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
CA2223078C (en) * 1995-06-07 2008-11-25 Gilead Sciences, Inc. Nucleic acid ligands that bind to and inhibit dna polymerases
US6229002B1 (en) * 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
EP0922114B1 (de) 1996-08-26 2003-10-29 Genetico Ltd. Katalytische nukleinsäuren und deren medizinische verwendung
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
DE69735292T2 (de) 1996-10-25 2006-10-19 Gilead Sciences, Inc., Foster City Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe
AU724627B2 (en) * 1996-12-19 2000-09-28 Yale University Bioreactive allosteric polynucleotides
US6001067A (en) * 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
DE19743518A1 (de) 1997-10-01 1999-04-15 Roche Diagnostics Gmbh Automatisierbare universell anwendbare Probenvorbereitungsmethode
AU3909199A (en) 1997-12-15 1999-07-05 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US5988142A (en) * 1997-12-22 1999-11-23 Stanadyne Automotive Corp. Duration control of common rail fuel injector
US6087102A (en) * 1998-01-07 2000-07-11 Clontech Laboratories, Inc. Polymeric arrays and methods for their use in binding assays
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US6399302B1 (en) * 1998-08-21 2002-06-04 University Of Virginia Patent Foundation Signal generating oligonucleotide-based biosensor
IL126731A0 (en) 1998-10-23 1999-08-17 Intelligene Ltd A method of detection
IL126732A0 (en) 1998-10-23 1999-08-17 Intelligene Ltd Pro drug
AU772881B2 (en) 1998-11-03 2004-05-13 Yale University Multidomain polynucleotide molecular sensors
AU777823B2 (en) 1999-01-19 2004-11-04 Somalogic, Inc. Method and apparatus for the automated generation of nucleic acid ligands
US6329145B1 (en) * 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
ES2459745T3 (es) 1999-05-14 2014-05-12 Brandeis University Detección basada en aptámero
US6506887B1 (en) * 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
WO2001066721A2 (en) 2000-03-06 2001-09-13 Ribozyme Pharmaceuticals, Inc. Nucleic acid sensor molecules
AU2001266917A1 (en) 2000-06-15 2001-12-24 Board Of Regents Allosterically regulated ribozymes
CA2412664A1 (en) * 2000-06-15 2001-12-20 Board Of Regents The University Of Texas System Regulatable, catalytically active nucleic acids
CA2418724A1 (en) 2000-09-13 2002-03-21 Archemix Corporation Target activated nucleic acid biosensor and methods of using same
WO2003014375A2 (en) 2001-08-09 2003-02-20 Archemix Corporation Nucleic acid sensor molecules and methods of using same
US20030219422A1 (en) * 2001-11-15 2003-11-27 Noxxon Pharma Ag Allosteric ribozymes and uses thereof

Also Published As

Publication number Publication date
US20060084109A1 (en) 2006-04-20
EP1543158A4 (de) 2007-06-06
AU2003261264A1 (en) 2004-02-16
JP2005533862A (ja) 2005-11-10
US7960102B2 (en) 2011-06-14
EP1543158B1 (de) 2011-07-13
WO2004011680A1 (en) 2004-02-05
CA2492463A1 (en) 2004-02-05
EP1543158A1 (de) 2005-06-22
US20040110235A1 (en) 2004-06-10
AU2003261264B2 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
EP1543158A4 (de) Regulierte aptamer-therapeutika
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
EA201791669A2 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
MXPA05008222A (es) Metodos y composiciones para administrar agentes terapeuticos y de diagnostico.
MEP35308A (en) COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
DE60320095D1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
UY28945A1 (es) Derivados de pirrolopiridina
EP1781277A4 (de) Kombinationspräparat
WO2004026260A3 (en) Prophylactic and therapeutic hiv aptamers
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
NO20080781L (no) GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer
JOP20230173A1 (ar) أشطر إطالة العمر-النصفي وطرق استخدامها
CY1112440T1 (el) Απογλυκοζυλιωμενη και αποσιαλιδωμενη μακρα πεντραξινη ρτχ3
MX2009006670A (es) Composicion farmaceutica que usa el aliskiren y el avosentan.
ATE435868T1 (de) Homogemcitabine
ATE406172T1 (de) Verwendung von löslichem cd14 zur behandlung von erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties